Figure 2 | Scientific Reports

Figure 2

From: The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study

Figure 2

Cumulative incidence of major adverse cardiovascular (CV) events after the initiation of each anti-inflammatory treatment. Cumulative incidence of major CV events every 3 months stratified according to treatment. The difference among each cohort and the control cohort remained statistically significant until the end of the observation period (P < .001 at 15 and 30 months), except for the methotrexate cohort (P = .98 at 15 months and P = .24 at 30 months). CV: cardiovascular.

Back to article page